Login to Your Account

GSK, Genmab Deal Tops All: $2.1B For Phase III Antibody

By Randall Osborne

Wednesday, December 20, 2006
Hailed as the biggest biotech licensing deal ever, Genmab A/S' potential DKK12 billion (US$2.1 billion) pact with London-based GlaxoSmithKline plc gives the London-based pharma giant worldwide rights to the late-stage HuMax-CD20, and a stake of just more than 10 percent in Genmab. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription